Intelligent Blood Tester to Detect Malaria Parasitemia

Votes: 13
Views: 2589
Medical

Problem statement:
Detection and calculation of malaria parasitemia in human blood smear

Introduction:
Malaria represents a serious public health problem for humans and animals worldwide. Malaria is endemic in more than 100 countries while the majority of the cases occurs in tropic countries. Estimation of parasitemia (in stained blood smears) is an important parameter in malaria diagnosis and malaria research; however it is being perform manually since binging, which is a time consuming method. In contrast this study proposes a Python (Open CV) based image processing tool for easy, user friendly, accurate and cost effective calculation of parasitemia. During this process, initially the malaria positive blood smear image was acquired and a Python Code for Image Processing was developed which includes image decomposition, cell size estimation, morphological transformation and parasitemia calculation. Proposed tool resulted in 7.42% of parasitemia which in contrast to manual calculation (6.42% parasitemia), 90.00% accurate. Based on the above observations it can be concluded that the Python based image processing tool is a very effective approach of rapid calculation of parasitemia.

Proposed Technique:
A Python based automated image processing tool for accurate, rapid and user friendly calculation of malarial parasitemia has been purposed. For this purpose, pictures of stained blood samples were collected and analyzed by using proposed automatic tool to calculate parasite infected cells.

Voting

Voting is closed!

  • ABOUT THE ENTRANT

  • Name:
    Mahendra Swain
  • Type of entry:
    individual
  • Profession:
    Assistant Professor
  • Mahendra is inspired by:
    The serious threat posed by the spread of drug-resistant malaria in Africa has been widely acknowledged. Chloroquine resistance is now almost universal, and resistance to the successor drug, sulfadoxine-pyrimethamine (SP), is growing rapidly. Combination therapy has been suggested as being an available and potentially lasting solution to this impending crisis. However, the current cost of combination therapy, and especially that of artemisinin combination therapy (ACT), is potentially a serious drawback, even if a significant part of its cost is passed on to the end-user. If the question of cost is not successfully addressed this could lead to adverse results from the deployment of combination therapy as first-line treatment.
  • Patent status:
    none